Fighting Fake Imports? Health Foods Exported to China Still Need Local Authority Recommendation

Why It Matters

The tighter catalogue forces foreign health‑food manufacturers to secure local authority recommendation letters, raising compliance costs but enhancing product credibility in China’s lucrative market. It also differentiates regulatory pathways for traditional trade versus CBEC, reshaping entry strategies for exporters.

Key Takeaways

• Decree No. 280 effective June 1, 2026, replaces Decree 248
• Catalogue now lists 17 food categories, health foods retained
• Overseas factories must submit local authority recommendation letters
• CBEC imports bypass factory registration, treated as personal items
• Fake health‑food imports have spurred tighter customs scrutiny

Pulse Analysis

China’s latest customs overhaul, embodied in Decree No. 280, reflects a shift toward a more risk‑based, science‑driven regulatory framework. By consolidating the catalogue to 17 categories and keeping health foods under tighter scrutiny, the General Administration of Customs aims to protect consumers from counterfeit products while simplifying the approval process for legitimate overseas manufacturers. The decree’s five‑year validity period, with automatic extensions for most facilities, offers a predictable compliance horizon, yet the exclusion of meat‑based and edible‑bird‑nest producers signals continued vigilance for high‑risk items.

For health‑supplement exporters, the requirement to obtain recommendation letters from local competent authorities represents a new hurdle that is nevertheless less burdensome than full product registration within China. This approach acknowledges the prevalence of contract manufacturing abroad and leverages existing factory registrations to streamline market entry. Meanwhile, cross‑border e‑commerce (CBEC) shipments are treated as personal imports, sidestepping the factory‑registration mandate and creating a parallel pathway that many brands already exploit. Companies must therefore align their supply‑chain strategies with the dual tracks—general trade and CBEC—to optimize cost and speed to market.

The backdrop of recent fake‑import scandals, where domestically produced supplements masqueraded as U.S. brands and sold at premium prices, has amplified regulatory resolve. Chinese consumers continue to favor foreign‑origin health foods, especially from the United States, driving demand for authentic products. As a result, overseas manufacturers and Chinese distributors are likely to invest more in transparent sourcing, robust documentation, and compliance infrastructure. Future adjustments to the catalogue remain possible, suggesting that firms should adopt flexible compliance models to stay ahead of evolving customs expectations.